A clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors.
- Year invested 2015
- Investment Stage Early
- Board Members
- Sectors
- Investment Status Current
- Website ir.tempesttx.com
- Company Status IPO/Public (NASDAQ: TPST)